Prostate cancer screening: Clinical applications and challenges

Research output: Contribution to journalArticle

Abstract

Prostate cancer is a serious illness warranting appropriate screening measures. However, current screening tests that include prostate-specific antigen and digital rectal examination must be proven to save lives to be considered truly legitimate and appropriate public health tools. Even though these tests are associated with the diagnosis of disease, important questions remain as to how well these tests identify all disease and whether screening leads to interventions that save lives. Prostate cancer is undoubtedly a killer, yet there appear to be large numbers of detectable prostate cancers that are of little threat to life. Some men with this grade of cancer receive curative treatment, even though their disease does not require treatment. Some studies suggest that more than three of four men with screen-detected localized disease may not need treatment. One of the great challenges of cancer communications is how to convey the hope of prostate cancer screening while adequately acknowledging the boundaries of our knowledge. The current absence of an appropriate informed consent tool points to the necessity to develop an easy to understand informed consent that allows men to evaluate screening decisions with a clear understanding of what is known, what is not known, and what is believed to be true about prostate cancer screening.

Original languageEnglish (US)
Pages (from-to)353-357
Number of pages5
JournalUrologic Oncology: Seminars and Original Investigations
Volume22
Issue number4
DOIs
StatePublished - Jul 1 2004
Externally publishedYes

Fingerprint

Early Detection of Cancer
Prostatic Neoplasms
Informed Consent
Hope
Digital Rectal Examination
Prostate-Specific Antigen
Neoplasms
Therapeutics
Public Health
Communication

Keywords

  • Cancer
  • DRE
  • Overdiagnosis
  • PCPT
  • Prostate
  • PSA

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Prostate cancer screening : Clinical applications and challenges. / Brawley, Otis.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 22, No. 4, 01.07.2004, p. 353-357.

Research output: Contribution to journalArticle

@article{b0970ee2dddb4075af36d0582907c271,
title = "Prostate cancer screening: Clinical applications and challenges",
abstract = "Prostate cancer is a serious illness warranting appropriate screening measures. However, current screening tests that include prostate-specific antigen and digital rectal examination must be proven to save lives to be considered truly legitimate and appropriate public health tools. Even though these tests are associated with the diagnosis of disease, important questions remain as to how well these tests identify all disease and whether screening leads to interventions that save lives. Prostate cancer is undoubtedly a killer, yet there appear to be large numbers of detectable prostate cancers that are of little threat to life. Some men with this grade of cancer receive curative treatment, even though their disease does not require treatment. Some studies suggest that more than three of four men with screen-detected localized disease may not need treatment. One of the great challenges of cancer communications is how to convey the hope of prostate cancer screening while adequately acknowledging the boundaries of our knowledge. The current absence of an appropriate informed consent tool points to the necessity to develop an easy to understand informed consent that allows men to evaluate screening decisions with a clear understanding of what is known, what is not known, and what is believed to be true about prostate cancer screening.",
keywords = "Cancer, DRE, Overdiagnosis, PCPT, Prostate, PSA",
author = "Otis Brawley",
year = "2004",
month = "7",
day = "1",
doi = "10.1016/j.urolonc.2004.04.014",
language = "English (US)",
volume = "22",
pages = "353--357",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Prostate cancer screening

T2 - Clinical applications and challenges

AU - Brawley, Otis

PY - 2004/7/1

Y1 - 2004/7/1

N2 - Prostate cancer is a serious illness warranting appropriate screening measures. However, current screening tests that include prostate-specific antigen and digital rectal examination must be proven to save lives to be considered truly legitimate and appropriate public health tools. Even though these tests are associated with the diagnosis of disease, important questions remain as to how well these tests identify all disease and whether screening leads to interventions that save lives. Prostate cancer is undoubtedly a killer, yet there appear to be large numbers of detectable prostate cancers that are of little threat to life. Some men with this grade of cancer receive curative treatment, even though their disease does not require treatment. Some studies suggest that more than three of four men with screen-detected localized disease may not need treatment. One of the great challenges of cancer communications is how to convey the hope of prostate cancer screening while adequately acknowledging the boundaries of our knowledge. The current absence of an appropriate informed consent tool points to the necessity to develop an easy to understand informed consent that allows men to evaluate screening decisions with a clear understanding of what is known, what is not known, and what is believed to be true about prostate cancer screening.

AB - Prostate cancer is a serious illness warranting appropriate screening measures. However, current screening tests that include prostate-specific antigen and digital rectal examination must be proven to save lives to be considered truly legitimate and appropriate public health tools. Even though these tests are associated with the diagnosis of disease, important questions remain as to how well these tests identify all disease and whether screening leads to interventions that save lives. Prostate cancer is undoubtedly a killer, yet there appear to be large numbers of detectable prostate cancers that are of little threat to life. Some men with this grade of cancer receive curative treatment, even though their disease does not require treatment. Some studies suggest that more than three of four men with screen-detected localized disease may not need treatment. One of the great challenges of cancer communications is how to convey the hope of prostate cancer screening while adequately acknowledging the boundaries of our knowledge. The current absence of an appropriate informed consent tool points to the necessity to develop an easy to understand informed consent that allows men to evaluate screening decisions with a clear understanding of what is known, what is not known, and what is believed to be true about prostate cancer screening.

KW - Cancer

KW - DRE

KW - Overdiagnosis

KW - PCPT

KW - Prostate

KW - PSA

UR - http://www.scopus.com/inward/record.url?scp=3342983363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3342983363&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2004.04.014

DO - 10.1016/j.urolonc.2004.04.014

M3 - Article

C2 - 15283896

AN - SCOPUS:3342983363

VL - 22

SP - 353

EP - 357

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 4

ER -